A new MRI study of 615 adults found higher ultra-processed food intake was linked to more fat stored inside muscle tissue, even when calories were matched.

A Nature study of 27,885 people identified gene variants that predict GLP-1 weight loss and nausea risk, including one specific to Mounjaro users.

The FDA has approved Foundayo (orforglipron), a daily GLP-1 pill for weight loss with no fasting requirements. Average weight loss of 11.2% at 72 weeks.

The OASIS 4 trial found oral semaglutide 25 mg produced 13.6% weight loss over 64 weeks, comparable to injectable Wegovy. UK approval expected late 2026.

Mayo Clinic research found 4 obesity phenotypes that drive weight gain differently. When treatment matched a person's phenotype, weight loss nearly doubled.

A study of 8,000 patients found weight regain after stopping GLP-1 medications was far less than clinical trials predicted. Here's why.

Second Nature combines Mounjaro & Wegovy weight-loss medications with support from registered dietitians. NHS-used since 2017, with ~18-22% weight loss.

Second Nature's medication weight-loss programme will now be available to Vitality members. It combines weight-loss injections with habit change support.

How much does Ozempic cost? Where can you buy it? Should you be on Ozempic? Find out all the information you need on Ozempic before purchasing.

Microdosing Ozempic isn't clinically recommended in the UK. Ozempic is only approved people living with type 2 diabetes and can't be used for weight loss.